Astrazeneca: + 31% quarterly revenues, from vaccine 894 million dollars

(ANSA) - ROME, JULY 29 - AstraZeneca closes the first half with an increase in revenues of 23% to 15.5 billion dollars and a + 31% in the second quarter alone.

This is what we read in a note from the group.

From the anti Covid vaccines, revenues of 894 million (1,169 million in the half year) came. Excluding this contribution, explains Astrazeneca, revenues rose by 14% in the six-month period.

For the future the group sees further development also thanks to the recent acquisition of Alexion Pharma.

(HANDLE).